VOR

Over the past six months, Vor Biopharma's stock has been influenced by several events. Clinical trial progress and data include telitacicept demonstrating deep and durable minimal symptom expression in generalized myasthenia gravis, completion of enrollment in the global Phase 3 UPSTREAM MG trial, and plans to expand into ocular myasthenia gravis with a new global Phase 3 trial (UPSTREAM oMG) in early 2027. Positive results from the Phase 3 TELIGAN trial in IgA nephropathy in China were announced, and positive Phase 3 data for telitacicept in SLE in Chinese patients were published in the New England Journal of Medicine. The company initiated its global Phase 3 trial in primary Sjögren's disease (UPSTREAM SjD) and dosed its first patient. The company also reported several inducement equity grants to newly hired employees. Stock price fluctuations include a significant drop in September 2026 following a corporate presentation where management acknowledged regulatory and market hurdles and intense competition, leading investors to reevaluate clinical timelines. Earlier, in April 2026, there was a notable drop in short interest, and Jefferies Financial Group upgraded Vor Biopharma to a "strong-buy" rating, contributing to a "Moderate Buy" consensus recommendation from analysts. Insider transactions included Ra Capital Management, L.P. selling a significant number of shares in April 2026. A 1:20 reverse stock split occurred on September 19, 2025, impacting share price and outstanding shares. As of early October 2026, the stock traded between a 52-week low of $6.50 and a high of $38.31 or $49.64, with the price on September 30, 2026, at $19.08 per share, down from $39.26 per share on October 1, 2025.